552331-15-4

Usage

Uses

Used in Pharmaceutical Industry:
1-(5-Bromo-2-fluorophenyl)ethanol is used as a key intermediate in the synthesis of pharmaceuticals for its ability to be incorporated into complex molecular structures, contributing to the development of new drugs with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 1-(5-Bromo-2-fluorophenyl)ethanol serves as a precursor in the production of agrochemicals, such as pesticides and herbicides, due to its potential to enhance the effectiveness and selectivity of these compounds.
Used in Specialty Chemicals Industry:
1-(5-Bromo-2-fluorophenyl)ethanol is utilized as a building block in the synthesis of specialty chemicals, where its unique properties can be leveraged to create compounds with specific applications in various industries, such as materials science, fragrances, and dyes.
Used in Organic Synthesis:
As a versatile organic compound, 1-(5-Bromo-2-fluorophenyl)ethanol is employed in various organic synthesis processes, where its reactivity and functional groups can be manipulated to form a wide range of chemical products.

InChI:InChI=1/C8H8BrFO/c1-5(11)7-4-6(9)2-3-8(7)10/h2-5,11H,1H3

Upstream product

• 75-16-1 methylmagnesium bromide 
• 93777-26-5 5-bromo-2-fluorobenzaldehyde 
• 676-58-4 methylmagnesium chloride 

Downstream Products

• 1544741-07-2 (5aR,6S,6aS)-3-(1-(4-fluoro-2’,6’-dimethyl-4’-(3-(methylsulfonyl)propoxy)-[1,1’-biphenyl]-3-yl)ethoxy)-5,5a,6,6a-tetrahydrocyclopropa[4,5]cyclopenta[1,2-c]pyridine-6-carboxylic acid 
• 1544741-11-8 (5aR,6S,6aS)-3-(1-(4-fluoro-2’,6’-dimethyl-4’-(3-(methylsulfonyl)propoxy)-[1,1’-biphenyl]-3-yl)ethoxy)-5,5a,6,6a-tetrahydrocyclopropa[4,5]cyclopenta[1,2-c]pyridine-6-carboxylic acid ethyl ester 
• 1544741-08-3 4-bromo-2-(1-bromoethyl)-1-fluorobenzene 
• 1374001-10-1 C₁₈H₁₅F₂N₅ 
• 1374001-23-6 C₁₃H₁₂BrFN₄ 
• 1374001-22-5 C₁₂H₁₃BrFN₃ 
• 1374001-21-4 C₁₇H₂₁BrFN₃O₂ 
• 1374001-20-3 tert-butyl [(2S)-2-(5-bromo-2-fluorophenyl)-4-oxobutan-2-yl]carbamate 
• 1374001-19-0 C₁₆H₂₁BrFNO₂ 
• 1374001-18-9 (S)-1-(5-bromo-2-fluoro-phenyl)-1-methyl-but-3-enylamine 
• 1374001-17-8 N-[(1S)-1-(5-bromo-2-fluoro-phenyl)-1-methyl-but-3-enyl]-2-methyl-propane-2-sulfinamide 
• 1194044-26-2 (R)-2-methyl-propane-2-sulfinic acid [1-(5-bromo-2-fluoro-phenyl)-ethylidene]-amide 
• 1374001-16-7 C₁₈H₁₅F₂N₅ 
• 1422359-86-1 C₁₃H₁₂BrFN₄ 

Relevant academic research and scientific papers

TREATMENT OF FIBROSIS WITH IRE1 SMALL MOLECULE INHIBITORS

Provided herein are methods of using IRE1 small molecule inhibitors in combination therapies for treating fibrosis in a subject. The IRE1 small molecule inhibitors described herein may be used in combination therapies for treating fibrosis

IRE1 SMALL MOLECULE INHIBITORS

Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a

COMBINATION THERAPIES WITH IRE1 SMALL MOLECULE INHIBITORS

Provided herein are methods of using IRE1 small molecule inhibitors in combination therapies for treating cancer in a subject. The IRE1 small molecule inhibitors described herein may be used in combination therapies for treating solid and hematologic cancers.

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

IRE1 SMALL MOLECULE INHIBITORS

Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.

IRE1 SMALL MOLECULE INHIBITORS

Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a

IRE1 SMALL MOLECULE INHIBITORS

Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.

Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer

A novel series of pyridin-3-amine derivatives were designed, synthesized, and evaluated as multitargeted protein kinase inhibitors for the treatment of non-small cell lung cancer (NSCLC). Hit 1 was first disclosed by in silico screening against fibroblast

FUSED AMINODIHYDROPYRIMIDINE DERIVATIVE

The present invention provides, for example, the following compound: wherein ring A is a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, X1—X2═X3 is CR5—CR6═CRs

Maximizing lipophilic efficiency: The use of Free-Wilson analysis in the design of inhibitors of acetyl-CoA carboxylase

This paper describes the design and synthesis of a novel series of dual inhibitors of acetyl-CoA carboxylase 1 and 2 (ACC1 and ACC2). Key findings include the discovery of an initial lead that was modestly potent and subsequent medicinal chemistry optimization with a focus on lipophilic efficiency (LipE) to balance overall druglike properties. Free-Wilson methodology provided a clear breakdown of the contributions of specific structural elements to the overall LipE, a rationale for prioritization of virtual compounds for synthesis, and a highly successful prediction of the LipE of the resulting analogues. Further preclinical assays, including in vivo malonyl-CoA reduction in both rat liver (ACC1) and rat muscle (ACC2), identified an advanced analogue that progressed to regulatory toxicity studies.